Efflux transporter-mediated interactions with atorvastatin-interesting findings with multiple substrates: Istradefylline, verapamil, and rifampicin

Journal of Clinical Pharmacology

Volumn 49, Issue 12, 2009, Pages 1492-1493

  Srinivas, Nuggehally R ^a  

^a ClinTec India International Pvt Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CYTOCHROME P450 3A4; GLYCOPROTEIN P; ISTRADEFYLLINE; NORVERAPAMIL; RIFAMPICIN; SILDENAFIL; VERAPAMIL;

DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG UPTAKE; HUMAN; LETTER; SINGLE DRUG DOSE; STEADY STATE;

ANTICHOLESTEREMIC AGENTS; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HEPTANOIC ACIDS; HUMANS; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PURINES; PYRROLES; RIFAMPIN; VERAPAMIL;

EID: 71549131614     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008328097     Document Type: Letter

References (11)

1. Rao N., Dvorchik B., Sussman N., et al. A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinsons disease, and atorvastatin. J Clin Pharmacol. 2008 ; 48: 1092-1098.
2. Benet LZ, Cummins CL, Wu CY Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm. 2004 ; 277: 3-9.
3. Benet LZ, Cummins CL, Wu CY Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab. 2003 ; 4: 393-398.
4. Choi DH, Shin WG, Choi JS Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil. Eur J Clin Pharmacol. 2008 ; 64: 445-449.
5. Lau YY, Huang Y., Frassetto L., Benet LZ Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007 ; 81: 194-204.
6. Treiber A., Schneiter R., Häusler S., Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 ; 35: 1400-1407.
7. Burgess G., Hoogkamer H., Collings L., Dingermanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol. 2008 ; 64: 43-50.
8. Kantola T., Kivisto KT, Neuvonen PJ Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 1998 ; 64: 177-182.
9. Backman JT, Luurila H., Neuvonen M., Neuvonen PJ Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther. 2005 ; 78: 154-167.
10. Shitara Y., Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006 ; 112: 71-105.
11. Oswald S., Giessmann T., Luetjohann D. Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clin Pharmacol Ther. 2006 ; 80: 477-485.